Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | ITK | Q08881 | 8/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.38 |
| ▸ | IL2 | P60568 | 3/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134571 | 0.97 | FGFR1 (0.41) | FGFR1FGFR2FGFR3KDRITK | |
| SCHEMBL4129282 | 0.92 | FGFR1 (0.43) | FGFR1FGFR2FGFR3KDRITK | |
| SCHEMBL4124997 | 0.89 | FGFR1 (0.41) | FGFR1FGFR2FGFR3KDRITK | |
| SCHEMBL3933348 | 0.88 | ITK (0.45) | FGFR1FGFR2FGFR3KDRITK | |
| Trifluoroacetic Acid SCHEMBL4142647 | 0.87 | FGFR1 (0.40) | FGFR1FGFR2FGFR3KDRITK | |
| SCHEMBL3927781 | 0.85 | ITK (0.43) | FGFR1FGFR2FGFR3KDRITK | |
| SCHEMBL18833155 | 0.84 | ITK (0.34) | FGFR1FGFR2FGFR3KDRITK | |
| Trifluoroacetic Acid SCHEMBL4130036 | 0.84 | ITK (0.42) | FGFR1FGFR2FGFR3KDRITK | |
| SCHEMBL4130323 | 0.83 | FGFR1 (0.41) | FGFR1FGFR2FGFR3KDRPDPK1 | |
| Hydrochloric Acid SCHEMBL4134109 | 0.82 | FGFR1 (0.40) | FGFR1FGFR2FGFR3KDRPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041119-B1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2017-05-10 | — | — | EP | claimed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | claimed |
| EP-2041119-B1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2017-05-10 | — | — | EP | disclosed |
| EP-2041119-B1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2017-05-10 | — | — | EP | disclosed |
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | disclosed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | disclosed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | disclosed |
| EP-2041119-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | Aventis Pharma S.A. (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003857-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | RB1, CCNI, CDK2 | FGFR1 2171/4885FGFR2 1805/4885FGFR3 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.